Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
The MZL cohort of a phase 2 study saw the most success from the atezolizumab plus obinutuzumab and venetoclax regimen.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Glofitamab combos show high, durable responses in high-risk LBCL, per phase II COALITION trial in younger patients.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
NKTR-255 plus liso-cel shows promise in boosting CD8+ CAR T cells and improving remission in R/R LBCL.
Explore expert insights on bispecifics, CAR T-cell therapy, and emerging regimens for B-cell lymphomas.
The agent, investigational drug candidate ADX-2191, is a novel intravitreal injection formulation of methotrexate.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Zilovertamab vedotin plus R-GemOx shows promise in R/R DLBCL, with RP2D set at 1.75 mg/kg per WaveLINE-003 phase 2/3 trial.
Dr. Frederick Locke discussed the ZUMA-7 trial of axi-cel versus standard of care for patients with relapsed/refractory LBCL.
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.